Oncologie

, Volume 10, Issue 5, pp 295–298 | Cite as

Que reste-t-il de l’interféron en hématologie ?

Synthèse / Review Article
  • 24 Downloads

Résumé

L’interféron alpha est étudié en hématologie depuis la fin des années 1960. Il est utilisable dans de nombreuses indications mais, depuis l’avènement des thérapies ciblées, il semble nécessaire de revoir la littérature pour faire le point sur ses indications. L’activité immunomodulatrice de l’interféron lui a conféré une indication en première ligne dans le traitement des lymphomes folliculaires, y compris en combinaison avec le rituximab. En revanche, sa médiocre tolérance limite actuellement son utilisation. Pour les lymphomes de bas grade associés aux infections virales, l’interféron associé à des molécules antivirales garde tout son intérêt. Pour les lymphomes T, l’absence de consensus thérapeutique permet de proposer l’interféron en deuxième ou troisième ligne. Pour la leucémie myéloïde chronique, l’interféron a été supplanté par l’imatinib en traitement d’induction, mais des essais sont en cours en traitement d’entretien. Pour conclure, les indications de l’interféron en hématologie se restreignent peu à peu, mais de nouvelles voies de recherche semblent prometteuses notamment dans les leucémies.

Mots clés

Interféron Lymphome folliculaire Hépatite virale Leucémie 

Does interferon have still a role in haematology?

Abstract

Interferon alpha has been investigated in haematology since the end of the 60’s. It may be prescribed in various indications but the availability of the recently developed targeted therapies makes necessary to reassess these indications by a literature review. In patients with follicular lymphoma, interferon, combined or not with rituximab, is a first-line treatment given for its immuno-modulator activity. However, it has been shown to be poorly tolerated, which limits its use. In virus-related low-grade lymphomas, interferon combined with antiviral drugs is still of interest. In T-cell lymphomas, the lack of therapeutic consensus makes interferon an option as second-or third-line treatment. In chronic myeloid leukaemia, it has been replaced by imatinib for induction therapy, but ongoing trials assess its efficacy as maintenance treatment. In conclusion, the indications for interferon decrease gradually in haematology but new options may emerge, especially in leukaemia.

Keywords

Interferon Follicular lymphoma Viral hepatitis Leukaemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Carella AM (2007) Interferon-alpha (IFN-a) given alone to CML patients with undetectable disease after imatinib (IM) is able to maintain their complete molecular remission after IM discontinuation. ASH Annual Meeting Abstracts 110Google Scholar
  2. 2.
    Chiarion-Sileni V, Bononi A, Fornasa CV, et al. (2002) Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 95: 569–575PubMedCrossRefGoogle Scholar
  3. 3.
    Chiou TJ, Wang TH, Chao TY, et al. (2007) Randomized phase II trial of thalidomide alone versus thalidomide plus interferon-alpha in patients with refractory multiple myeloma. Cancer Invest 25: 140–147PubMedCrossRefGoogle Scholar
  4. 4.
    Dave SS, Wright G, Tan B, et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351: 2159–2169PubMedCrossRefGoogle Scholar
  5. 5.
    Davis TA, Maloney DG, Grillo-Lopez AJ, et al. (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 6: 2644–2652PubMedGoogle Scholar
  6. 6.
    Deenik W, van der Holt B, Verhoef GE, et al. (2007) High-vs low-dose cytarabine combined with interferon-alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. Ann Hematol 86: 117–125PubMedCrossRefGoogle Scholar
  7. 7.
    Gomez-Benito M, Balsas P, Carvajal-Vergara X, et al. (2007) Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of JAK1 and Bim and potentiation by rapamycin. Cell Signal 19: 844–854PubMedCrossRefGoogle Scholar
  8. 8.
    Hermine O, Allard I, Levy V, et al. (2002) A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 3: 276–282PubMedCrossRefGoogle Scholar
  9. 9.
    Hermine O, Dombret H, Poupon J, et al. (2004) Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 5: 130–134PubMedCrossRefGoogle Scholar
  10. 10.
    Hermine O, Lefrere F, Bronowicki JP, et al. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347: 89–94PubMedCrossRefGoogle Scholar
  11. 11.
    Hochhaus A, Neubauer A, Mueller M, et al. (2007) Sustained molecular responses with interferon-2a maintenance therapy after imatinib plus IFN induction treatment for chronic phase chronic myelogenous leukemia. ASH Annual Meeting Abstracts 110Google Scholar
  12. 12.
    Kaminski MS, Tuck M, Estes J, et al. (2005) 1311-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441–449PubMedCrossRefGoogle Scholar
  13. 13.
    Knobler E (2004) Current management strategies for cutaneous T-cell lymphoma. Clin Dermatol 22: 197–208PubMedCrossRefGoogle Scholar
  14. 14.
    Melillo L, Valente D, Tieghi A, et al. (2007) Favourable outcome of pregnancy in essential thrombocythemia (ET) patients treated with interferon-alpha. A Report from the Registro Italiano Trombocitemia (RIT). ASH Annual Meeting Abstracts 110Google Scholar
  15. 15.
    Morris GJ, Millenson MM, Padavic-Shaller K, et al. (2004) Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin’s lymphoma. Haematologica 89: 1484–1491PubMedGoogle Scholar
  16. 16.
    Mounier N, Socie G, Gisselbrecht C (2002) High-dose therapy for indolent lymphoma. Crit Rev Oncol Hematol 41: 225–239PubMedCrossRefGoogle Scholar
  17. 17.
    Offidani M, Polloni C, Corvatta L, et al. (2007) Thalidomide-dexamethasone vs interferon-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma (MM): final analysis of a prospective, randomized study. ASH Annual Meeting Abstracts 110Google Scholar
  18. 18.
    Rohatiner AZ, Gregory WM, Peterson B, et al. (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23: 2215–2223PubMedCrossRefGoogle Scholar
  19. 19.
    Saba C, Brice P, Haioun C, et al. (2004) Phase II Study of PEG-Intron in Combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated. American society of clinical oncology. 40th annual meeting, June 5–8 2004, New-Orleans, Louisiane, USA. abst 6571. J Clin Oncol 22Google Scholar
  20. 20.
    Sacchi S, Federico M, Vitolo U, et al. (2001) Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low-grade non-Hodgkin’s lymphoma. Haematologica 86: 951–958PubMedGoogle Scholar
  21. 21.
    Salles G, Mounier N, Guibert S, et al. (2007) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: final analysis of the GELA-GOE-LAMS FL2000 study with a 5-year follow-up. ASH Annual Meeting Abstracts 110Google Scholar
  22. 22.
    Solal-Celigny P, Lepage E, Brousse N, et al. (1998) Doxorubicin-containing regimen with or without interferon-alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’étude des lymphomes folliculaires 86 trial. J Clin Oncol 16: 2332–2338PubMedGoogle Scholar
  23. 23.
    Solal-Celigny P, Roy P, Colombat P (2004) Project. TIFLPF. Follicular lymphoma international prognostic index. Blood 104: 1258–1265PubMedCrossRefGoogle Scholar
  24. 24.
    Swinnen LJ (2001) Organ transplant-related lymphoma. Curr Treat Options Oncol 2: 301–308PubMedCrossRefGoogle Scholar
  25. 25.
    Vallisa D, Bernuzzi P, Arcaini L, et al. (2005) Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol 23: 468–473PubMedCrossRefGoogle Scholar
  26. 26.
    Wotherspoon AC, Dogan A, Du MQ (2002) Mucosa-associated lymphoid tissue lymphoma. Curr Opin Hematol 9: 50–55PubMedCrossRefGoogle Scholar
  27. 27.
    Xiang Z, Zhao Y, Mitaksov V, et al. (2007) Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2007 Dec 26Google Scholar
  28. 28.
    Zhang C, Cui G, Chen Y, Fan K (2007) Antitumor effect of interferon-on U937 human acute leukemia cells in vitro and its molecular mechanism. J Huazhong Univ Sci Technology Med Sci 27: 513–515CrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2008

Authors and Affiliations

  1. 1.Service d’oncohématologie, clinique universitaire des spécialités médicaleshôpital l’Archet, CHU de NiceNiceFrance

Personalised recommendations